lutetium dotatate lu-177 (Lutathera) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA
AACT Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
DOTA-TATE is an eight amino acid long peptide, with a covalently bonded DOTA bifunctional chelator.   Wikipedia

Chemistry

  • SMILES: [177Lu+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN3CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC3)C(=O)N[C@@H](CC4=CC=C(O)C=C4)C(=O)N[C@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
  • InChIKey: XOPYQJXRGHFPOH-NZMVMCJSSA-K
  • Mol. Mass: 1595.559
  • ALogP: Missing data
  • ChEMBL Molecules:
    lutetium dotatate lu-177  
    lutetium oxodotreotide lu-177  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$37407.1400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(177lu-dotaotyr3)octreotate | 177lu dota-tate | 177lu-dotatate | 177lu-dota-tate | 177lu-edotreotide | 177lu-octreotate | (177lutetium-dota(o)tyr3)octreotate | dotatate-177lu | lu177 dota-tate | lu-177 dotate | lutate | lutetium dotatate lu-177

Organizations (59)

Research & Development (58)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (32)

Approved Indications (1)


 

Neuroendocrine Tumors

Experimental Indications - Clinical Trial Phases 1-4 (32)


 

Breast Neoplasms (Phase 2)

Carcinoid Heart Disease (Phase 2)

Carcinoid Tumor (Phase 2)

Carcinoma, Merkel Cell (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Clinical Trial, Phase I (Phase 1)

Diffuse Intrinsic Pontine Glioma (Phase 1/Phase 2)

Drugs, Investigational (Phase 2)

Ependymoma (Phase 1/Phase 2)

Glioblastoma (Phase 1)

Glioma (Phase 2)

Intestinal Neoplasms (Phase 3)

Lung Neoplasms (Phase 3)

Malignant Carcinoid Syndrome (Phase 2)

Medulloblastoma (Phase 1/Phase 2)

Meningioma (Phase 2)

Mesothelioma (Phase 1)

Neoplasm Metastasis (Phase 2/Phase 3)

Neoplasms (Phase 1/Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 1/Phase 2)

Neuroblastoma (Phase 2)

Neuroendocrine Tumors (Phase 3)

Pancreatic Neoplasms (Phase 3)

Paraganglioma (Phase 2)

Pheochromocytoma (Phase 2)

Pituitary Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Thymoma (Phase 1)

Thymus Neoplasms (Phase 3)

Thyroid Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 55
  • # of Trial Organizations: 58

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue